EKTA.B

48.94

+0.2%↑

EKTA.B

48.94

+0.2%↑

EKTA.B

48.94

+0.2%↑

EKTA.B

48.94

+0.2%↑

EKTA.B

48.94

+0.2%↑

Search

Vivesto AB

Chiusa

0

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

Massimo

Metriche Chiave

By Trading Economics

Entrata

-1.2M

-9.5M

EPS

-0.018

Dipendenti

4

Dividendi

By Dow Jones

Utili prossimi

11 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1.1M

129M

Apertura precedente

0

Chiusura precedente

0

Vivesto AB Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 ott 2025, 16:58 UTC

Utili

BMW Trims 2025 View, Citing Weaker Performance in China

7 ott 2025, 23:43 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 ott 2025, 23:36 UTC

Discorsi di Mercato

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 ott 2025, 23:19 UTC

Discorsi di Mercato

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 ott 2025, 22:50 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 ott 2025, 22:50 UTC

Discorsi di Mercato

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 ott 2025, 22:40 UTC

Discorsi di Mercato

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 ott 2025, 21:56 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

7 ott 2025, 21:56 UTC

Discorsi di Mercato

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

7 ott 2025, 20:44 UTC

Azioni calde

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 ott 2025, 19:42 UTC

Discorsi di Mercato

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 ott 2025, 19:23 UTC

Acquisizioni, Fusioni, Takeovers

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 ott 2025, 19:07 UTC

Discorsi di Mercato

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 ott 2025, 19:02 UTC

Discorsi di Mercato

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 ott 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

7 ott 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

7 ott 2025, 16:20 UTC

Discorsi di Mercato

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 ott 2025, 16:15 UTC

Discorsi di Mercato

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 ott 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

7 ott 2025, 15:37 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 ott 2025, 15:37 UTC

Discorsi di Mercato

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 ott 2025, 15:33 UTC

Discorsi di Mercato

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 ott 2025, 15:25 UTC

Discorsi di Mercato

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 ott 2025, 15:15 UTC

Discorsi di Mercato

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 ott 2025, 15:04 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

7 ott 2025, 15:04 UTC

Discorsi di Mercato

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 ott 2025, 14:56 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 ott 2025, 14:56 UTC

Discorsi di Mercato

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 ott 2025, 14:52 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Confronto tra pari

Modifica del prezzo

Vivesto AB Previsione

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
help-icon Live chat